Low-flow ECCO
Acute respiratory distress syndrome
Carbon dioxide tension
Extracorporeal removal
Pulmonary vascular dysfunction
Renal replacement
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
15 Jan 2024
15 Jan 2024
Historique:
received:
21
02
2023
revised:
12
12
2023
accepted:
14
12
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
epublish
Résumé
Hypercapnia worsens lung vascular dysfunction during acute respiratory distress syndrome (ARDS). We tested whether an extracorporeal carbon dioxide removal (ECCO We planned to prospectively include 20 patients with moderate-to-severe ARDS, pulmonary vascular dysfunction on echocardiography, and PaCO Only eight patients were included, and the study was stopped due to worldwide shortage of ECCO This pilot study testing showed a narrow efficacy and high rate of membrane thrombosis with the first version of the system. Improved versions should be tested in future trials. Registered at clinicaltrials.gov, identifier: NCT03303807, Registered: October 6, 2017, https://clinicaltrials.gov/ct2/show/NCT03303807.
Sections du résumé
Background
UNASSIGNED
Hypercapnia worsens lung vascular dysfunction during acute respiratory distress syndrome (ARDS). We tested whether an extracorporeal carbon dioxide removal (ECCO
Methods
UNASSIGNED
We planned to prospectively include 20 patients with moderate-to-severe ARDS, pulmonary vascular dysfunction on echocardiography, and PaCO
Results
UNASSIGNED
Only eight patients were included, and the study was stopped due to worldwide shortage of ECCO
Conclusions
UNASSIGNED
This pilot study testing showed a narrow efficacy and high rate of membrane thrombosis with the first version of the system. Improved versions should be tested in future trials.
Trial registration
UNASSIGNED
Registered at clinicaltrials.gov, identifier: NCT03303807, Registered: October 6, 2017, https://clinicaltrials.gov/ct2/show/NCT03303807.
Identifiants
pubmed: 38226285
doi: 10.1016/j.heliyon.2023.e23878
pii: S2405-8440(23)11086-3
pmc: PMC10788508
doi:
Banques de données
ClinicalTrials.gov
['NCT03303807']
Types de publication
Journal Article
Langues
eng
Pagination
e23878Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Pr Armand Mekontso Dessap reports financial support and equipment, drugs, or supplies were provided by 10.13039/100004702Baxter.